Teva Pharmaceutical Industries Sees Unusually High Options Volume (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw some unusual options trading activity on Wednesday. Stock traders acquired 39,816 call options on the company. This is an increase of approximately 85% compared to the typical volume of 21,570 call options.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.55% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. New Covenant Trust Company N.A. purchased a new position in Teva Pharmaceutical Industries in the first quarter valued at about $28,000. EntryPoint Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $30,000. UMB Bank n.a. increased its position in Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares during the period. Smithfield Trust Co raised its position in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $50,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA traded down $0.02 during midday trading on Thursday, hitting $16.57. 9,728,120 shares of the stock were exchanged, compared to its average volume of 9,236,628. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The company has a market capitalization of $18.77 billion, a price-to-earnings ratio of -19.49, a P/E/G ratio of 1.30 and a beta of 0.87. The business has a 50-day moving average price of $17.60 and a two-hundred day moving average price of $17.35. Teva Pharmaceutical Industries has a one year low of $9.35 and a one year high of $19.31.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on TEVA shares. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Finally, Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.